These authors contributed equally to this work. Luteolin (39, 49, 5, is a natural flavonoid that exists in several types of vegetables, fruits, and medicinal herbs that inhibits tumorigenesis in different types of cancer. In this study, we demonstrate luteolin-mediated regulation of cell apoptosis in a gastric cancer cell line through inhibition of the apoptosis regulatory protein Bcl-2. MTT and flow cytometric analysis indicate that luteolin inhibits cell proliferation and induces apoptosis in gastric cancer cells. Quantitative real-time polymerase chain reaction (qRT-PCR)
Introduction
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression in a posttranscriptional manner by triggering either mRNA degradation or translational repression through binding to the 3-untranslated region (3-UTR) of target mRNA (1) . Mature miRNA strands are incorporated into an RNA-induced silencing complex (RISC), which guides it to mRNA targets. Over 1,000 miRNA sequences in the human genome have been annotated in the latest version of the miRBase (2) . In the past several years, it has become clear that miRNAs contribute to most, if not all, basic biological processes, including embryonic stem cell differentiation, several metabolic pathways, cell proliferation, apoptosis, and signal transduction (3) .
Luteolin (39, 49, 5, 7-tetrahydroxyflavone) is a natural flavonoid that exists in several types of vegetables, fruits, and medicinal herbs (4) . Plants rich in luteolin have been used as traditional Chinese medicines for the treatment of cancer, hypertension, and inflammatory diseases (5) (6) (7) . The anticancer characteristics of luteolin are associated with apoptosis, DNA damage, and protein kinases; they help to inhibit cancer cell proliferation and suppress metastasis and angiogenesis (8, 9) . Furthermore, luteolin can sensitize a variety of cancer cells to Volume 14 Number 6 December 2015 Technology in Cancer Research & Treatment 2014 June 30. Epub ahead of print therapeutically induced cytotoxicity through suppressing cell survival pathways and stimulating apoptosis signaling (10) .
Gastric cancer is one of the most common cancers worldwide. In 2008, an estimated 989,600 new cases of gastric cancer were diagnosed and 738,000 deaths were attributed to gastric cancer, accounting for 8% of the total cancer cases and 10% of the total cancer deaths worldwide (11) . China, Japan, Eastern Europe, and Latin America are areas with high incidences of gastric cancer (12) . Some patients with advanced gastric cancer initially respond to chemotherapy but gradually become resistant (13) . Thus, new methods to improve the clinical response to gastric cancer are required. Luteolin was previously reported to inhibit the development of a series of solid tumors (8) (9) (10) . Some findings indicate the anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer (14) , however, the further details of the molecular mechanism involved in this effect remain controversial.
In the present study, we report the luteolin can decrease Bcl-2 expression partly through upregulating miR-34a expression in gastric cancer. Our results suggest that the miR-34a pathway plays an important role in luteolin-induced apoptosis in gastric cancer cells.
Materials and Methods

Clinical Samples
Twelve adult gastric cancer patients who were diagnosed at the First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China between September 2010 and June 2012 were included in the analysis. The tumor samples were resected during surgery, and at the same time, matched non-tumor adjacent tissue was obtained from a segment of the resected specimens that was the farthest from the tumor (5 cm). All the samples were divided into two parts; one was immediately snap-frozen in liquid nitrogen and stored at 280°C, and the other was stored in formalin for pathological analysis. Standard histopathological investigations, including hematoxylin & eosin (H&E), staining were independently performed by two pathologists. Approval for this study was obtained from the Institute Ethics Committee. Informed consent was obtained from all subjects in accordance with the Declaration of Helsinki (1975) .
Cell Lines and Culture
BGC-823 and SGC-7901 human gastric carcinoma cell lines were purchased from the National Institute of Cells, Shanghai, China. Cultured cells were grown as monolayers in RPMI 1640 media (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin and 100 mg/mL streptomycin in a humidified incubator containing 5% CO 2 at 37°C. Luteolin was purchased from Nanjing TCM Institute of Chinese Materia Medica, China and dissolved in dimethyl sulfoxide (DMSO). Its molecular formula is C 15 H 10 O 6 (CAS No: 491-70-3, Mol. Wt.: 286.24).
RNA Extraction and miRNA qRT-PCR
Total RNA from the specimens and cultured cells were isolated using the TRIzol total RNA isolation reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Total RNA (10 ng) was reverse transcribed, and mature miRNA expression was quantified following a standard microRNA stem-loop RT-PCR assay protocol (Roche, Mannheim, Germany) using SYBR green on the Rotor-Gene 3000 RT-PCR Detection System (Corbett Research, Mortlake, Australia). The expression of miRNAs was calculated relative to U6 small nuclear RNA. Changes in expression were calculated using the ΔΔC t method. The ΔC t values were calculated by subtracting the C t of snRNA U6 from the C t of the miRNA of interest (ΔC t 5 C t miRNA 2 C t U6 snRNA). The ΔΔC t was calculated by subtracting the ΔC t of the reference sample from the ΔC t of each sample. The 2 2ΔΔC t was calculated for each sample and divided by the control sample value to obtain the relative miRNA expression level. The following primers were used respectively, hsa-miR-34a: reverse primer, GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CAA CC upstream primer, 5-CGC GTG GCA GTG TCT TAG CT-3 downstream primer, 5-GTG CAG GGT CCG AGG T-3 Pri-miR-34a expression was performed using TaqMan Pri-miRNA assays (Applied Biosystems, USA). 50 ng total RNA was converted to first-strand cDNA with miRNA-specific primers, followed by RT-PCR with TaqMan probes. All samples were normalized to U6 snRNA.
Bcl-2 mRNA RT-PCR Analysis
Total RNA was used to synthesize cDNA using the cDNA Reverse Transcription Kit (Invitrogen) according to the manufacturer's protocol. The following primers were used for each molecule: for Bcl-2, 5-CAG AAT CCT CTG GAA CTT GAG G-3 (sense) and 5-GGT CTC CGA ATG TCT GGA AG-3 (antisense); for GAPDH, 5-ATG GGG AAG GTG AAG GTCG-3 (sense) and 5-TTACTCCTTGGAG-GCCATGTG-3 (antisense). The total reaction volume was 20 μL and contained 13 Quantitect SYBR Green mix (QIAGEN, Hilden, Germany), 13 Quantitect Primer mix, and 1.2 μL cDNA. All reactions were performed in a Rotor-Gene 3000 RT-PCR Detection System (Corbett Research).
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Western Blotting
Total protein was extracted from gastric cancer tissues and gastric cancer cells using a Total Protein Extraction Kit (KeyGenTec, Nanjing, China), according to the manufacturer's instructions. The concentration was measured by BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts of total protein were separated by SDS-PAGE on 10% polyacrylamide gels and then transferred to PVDF membranes. The membrane was incubated with antibodies directed against Bcl-2 (Cell Signaling Technology, Beverly, MA, USA) and GAPDH (KangChen, Beijing, China). After incubation with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies, bands were detected using the Western Lightning Chemiluminescence Reagent (Sigma), and Bcl-2 protein expression was quantified and normalized to the band intensities of GAPDH using Quantity One software (Bio-Rad, Hercules, CA, USA).
Transfection of miRNA Antisense and miRNA Mimics
BGC-823, SGC-7901 were plated at 80% confluence in RPMI-containing normal serum medium on 6-well plates for 24 h. MiR-34a mimic, negative control mimic, miR-34a antisense (Invitrogen), and scrambled control were transfected using Lipofectamine 2000 (Invitrogen) for 6 h before the media was changed to RPMI with normal serum. At 24 or 48 h after transfection, the cells were changed to low-serum medium and treated with vehicle (0.1% DMSO) or luteolin (20 mM) for further analysis.
Cell Proliferation Assay
Cells were plated at 80% confluence, and 100 nM miR-34a mimic or 100 nM negative control mimic were transfected using Lipofectamine 2000 (Invitrogen) for 6 h before the cells were trypsinized and seeded into 96-well culture plates at a density of 5,000 cells/well in growth medium supplemented with 10% serum. The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazoliumbromide) assay was performed 24 or 48 h posttransfection, and absorbance was measured using a spectrophotometer (Thermo Fisher, Waltham, MA, USA) at 490 nm. Each assay was performed in triplicate with three independent replicates.
Flow Cytometric Analysis
To assay the effect of luteolin on cell apoptosis, BGC-823 and SGC-7901 cells were exposed to different drugs for 48 h. The cultured cells were collected by centrifugation and resuspended in solution containing Annexin V-FITC and propidium iodide (PI) (BD Biosciences, Franklin Lakes, NJ, USA). Cells were analyzed by flow cytometry with excitation wavelength 5 488 nm and emission wavelength 5 530 nm for Annexin V-FITC detection (FL1 channel). A filter 600 nm was used for PI detection (FL2 channel). Electronic compensation of the instrument was required to exclude overlapping of the two emission spectra.
Results
MiR-34a is Frequently Downregulated in Gastric Cancer
We examined miR-34a expression in primary gastric cancer tissues and pair-matched adjacent non-tumor tissues using qRT-PCR, to determine whether miR-34a expression is associated with gastric cancer. Compared to non-tumor tissues, miR-34a expression was decreased in 8/12 (66.7%) of the cancer tissues ( Figure 1A ). The mean  SEM expression of miR-34a in gastric cancer tissues was significantly lower than in normal tissues (p  0.01) ( Figure 1B ). 
Luteolin Upregulated Pri-miR-34a and miR-34a Expression in Gastric Cancer Cell Lines
We also investigated whether luteolin could upregulate Pri-miR-34a or miR-34a expression in BGC-823 and SGC-7901 cell lines. The RT-PCR results indicated that that Pri-miR-34a and miR-34a expression were significantly increased after being treatment with 20, 40, or 80 μM luteolin (Figure 2) .
Luteolin Downregulated Bcl-2 Expression and Inhibited Cell Proliferation
Bcl-2 is overexpressed in many types of cancers, including lung cancer, breast cancer, gastrointestinal cancer, leukemia, and lymphoma (15) . In this study, we found that luteolin downregulated Bcl-2 expression and effectively inhibited cell proliferation in gastric cancer cells. Bcl-2 mRNA and protein levels were detected by qRT-PCR and western blotting, respectively, after BGC-823 and SGC-7901 cells were treated with different concentrations of luteolin (20, 40, or 80 μM). As indicated in Figure 3 , luteolin downregulated Bcl-2 expression in a concentration-dependent manner. The mRNA levels of Bcl-2 in BGC-823 and SGC-7901 cells were decreased in response to treatment with 20, 40, and 80 μM luteolin at 48 h compared with the control group ( Figure 3A and 3B). The protein levels of Bcl-2 in the gastric cancer cells were significantly decreased after 48 h treatment with 20, 40, and 80 μM luteolin ( Figure 3C and 3D ). Figure 3E and 3F, treatment of BGC-823 and SGC-7901 cells with luteolin resulted in dose-and timedependent decreases in cell viability.
As shown in
miR-34a Overexpression Decreased Bcl-2 Expression and Induced Apoptosis in Gastric Cancer Cells
Putative human protein-coding gene targets of miR-34a were identified using miRanda, TargetScan, and PicTar to characterize miR-34a function in gastric carcinogenesis (16) Bcl-2 was predicted by both TargetScan and PicTar. Many articles have reported that Bcl-2 is a target of miR-34a (17) (18) (19) . To further investigate the role of miR-34a in gastric carcinogenesis, we transfected the gastric cell lines BGC-823 and SGC-7901 with miR-34a mimic to overexpress miR-34a. Subsequent qRT-PCR analysis confirmed that expression of mature miR-34a was significantly increased in cells transfected with miR-34a mimic compared to the negative control cells (data not shown). Overexpression of miR-34a in BGC-823 and SGC-7901 cells led to significantly reduced expression of Bcl-2 protein ( Figure 4A and 4B) ; however, Bcl-2 mRNA expression was not significantly affected (data not shown).
Cell apoptosis was also examined by the Annexin V/PI method ( Figure 4C ). Untreated cells were primarily Annexin V-FITC-and PI-negative, indicating that they were viable and not undergoing apoptosis. After treatment, there were three populations of cells: cells that were viable and not undergoing apoptosis (Annexin V-FITC-and PI-negative), cells undergoing apoptosis (Annexin V-FITC-positive and PI-negative), and cells that were in end-stage apoptosis or necrotic (Annexin V-FITC-and PI-positive). Overexpression of miR-34a promoted apoptosis in SGC-7901 cells; the apoptosis rates were 26.7% (BGC-823) and 24.7% (SGC-7901) in the miR-34a mimic-transfected gastric cancer cells compared to control cells (5.8%, BGC-823; 5.9%, SGC-7901).
Anti-miR-34a Oligonucleotides (AMO) Partly Reversed Luteolin-induced Down-regulation of Bcl-2 in Gastric Cells
To further confirm the relationship among miR-34a, Bcl-2, and luteolin, we assessed Bcl-2 protein levels by western blotting after transfection with 50 nM AMO for 48 h in BGC-823 and SGC-7901 cells. As shown in Figure 5A and 5B, the protein levels of Bcl-2 in gastric cancer cells were significantly decreased after luteolin treatment. Moreover, AMO partly abolished the pro-apoptotic effect of luteolin on Bcl-2 protein expression ( Figure 5A and 5B). Figure 5C and 5D, luteolin-treated BGC-823 and SGC-7901 cells were transfected with 50 nM AMO for 24 or 48 h, and subsequent MTT assays revealed that AMO effectively reversed the luteolin-mediated inhibition of cell proliferation in BGC-823 and SGC-7901 cells.
As indicated in
To determine whether cells were undergoing apoptosis, changes in phosphatidylserine membrane localization were analyzed with Annexin V labeling. As revealed in Figure 5E and 5F, treatment with 40 μM luteolin for 48 h induced significant cell apoptosis (46.5% and 52.3% in BGC-823 and SGC-7901 cells, respectively), which was significant compared to untreated control cells (p  0.05). A significant increase in the number of cells undergoing apoptosis was observed 48 h after addition of 40 μM luteolin as shown in Figure 5E . However, AMO effectively reversed luteolin-induced gastric cancer cell apoptosis in both BGC-823 (21.1% apoptosis rate) and SGC-7901 cells (20.1% apoptosis rate).
Discussion
Luteolin is a common dietary flavonoid that is found in many plants and foods. Luteolin has been reported to inhibit the development of various solid tumors. It is a highly pleiotropic molecule that modulates numerous targets, including the activation of transcription factors, receptors, kinases, cytokines, enzymes, and growth factors (20, 21) . In our study, luteolin downregulated Bcl-2 expression and induced apoptosis in human gastric cancer cell lines.
Bcl-2 is a very important member of a protein family comprised of regulators of programmed cell death in both normal and abnormal cells. It is a pro-survival protein that regulates apoptosis by preventing the release of pro-apoptotic factors from mitochondria (e.g., cytochrome c) and subsequent activation of a caspase cascade (22) . Luteolin was previously reported to inhibit the development of a series of solid tumors (8, 9) . In our study, luteolin treatment resulted in a significant downregulation of Bcl-2 in gastric cancer cells. These data suggest that Bcl-2 plays an important role in the antiproliferative effects of luteolin. However, the mechanism by which luteolin downregulates Bcl-2 expression is still unknown. Our data show for the first time that luteolin downregulates Bcl-2 expression via a miRNA pathway.
Gene expression regulation is very complicated. Cai et al. reported that luteolin decreased Bcl-2 expression by inhibiting the translocation of NF-κB (p65) (23) . Fu et al. hypothesized that luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress the constitutive activation of STAT3 (24) . Our data showed that luteolin downregulated Bcl-2 expression via a miR-34a-mediated pathway. However, whether other factors are involved in the regulation of this pathway is not known. Therefore, it is difficult to accurately calculate to what degree the down-regulation of Bcl-2 in the luteolin-treated cells is attributable to the action of miRNA.
Each miRNA typically targets hundreds of distinct mRNAs by binding to the 3-untranslated region (3-UTR) to trigger mRNA degradation or translational repression. In this study, we observed that miR-34a is frequently downregulated in gastric cancer tissues and cell lines, suggesting that reduced miR-34a expression is common in human gastric cancer. MiR-34a belongs to a conserved miRNA family with three members: miR-34a, b, and c. MiR-34a has been consistently found to be poorly expressed in several tumor and tumor-derived cell lines, and its upregulation induces apoptosis and cell-cycle arrest.
Several miR-34a targets have been reported, including c-myc, E2F3, and Bcl-2 (25) (26) (27) . More recently, Kastl et al. found that miR-34a is frequently downregulated in breast cancer, and it can modulate apoptosis and survival in breast cancer cells via targeting Bcl-2 mRNA (28). Li et al. also reported that miR-34a inhibits breast cancer cell proliferation and migration through down-regulation of Bcl-2 and SIRT1 (29) . In this study, luteolin decreased Bcl-2 mRNA and protein levels in gastric cancer cells. Although AMO reversed the luteolininduced down-regulation of Bcl-2 in gastric cancer cells, it is obvious that additional mechanisms other than the induction of miR-34a expression contribute to luteolin-induced Bcl-2 downregulation. MiR-34a can regulate a variety of mRNAs, and Bcl-2 is regulated by many other factors. Therefore, it is not a one-to-one correspondent regulation between miR-34a and Bcl-2. However, luteolin partially inhibited cell apoptosis through miR-34a-mediated Bcl-2 downregulation.
The molecular mechanisms leading to miR-34a upregulation by luteolin remain largely unknown. Paradoxically, transcriptional regulation of miRNAs, a critical step in modulating their expression, remains poorly understood. This is due to previous limitations in the methodologies available to study primary miRNA transcripts and deficits in promoter sequence characterization. Although the mechanisms underlying miRNA expression dysregulation in cancer are not yet fully understood, several lines of evidence suggest that epigenetic modification of the promoters may be involved (30) . The gene encoding miR-34a is located on human chromosome 1p36 and is therefore postulated to be located intergenically and transcribed via its own promoter. Recent studies have shown that miR-34a located within CpG islands can be transcriptionally regulated by DNA methylation and that the patterns of methylation vary between normal and cancerous cells (31, 32) . The tumor suppressor gene p53 was also shown to directly regulate miR-34a expression (33) . Influence of DNA damage response could be considered after exposure to luteolin. Upon DNA damage, p53 plays a crucial role to initiate apoptosis, leading to a transcriptional activation of miR-34a.
Further research is needed to determine whether luteolin can regulate the methylation of CpG islands neighboring the miR-34c promoter, control p53 binding to the miR-34a promoter, or regulate miR-34a degradation. Based on the results described here, we can draw the conclusion that luteolin can decrease Bcl-2 expression partly through upregulating miR-34a expression. This study shows for the first time that the miR-34a pathway plays an important role in the luteolin-induced apoptosis in gastric cancer cells.
